Broxyquinoline targets NLRP3 to inhibit inflammasome activation and alleviate NLRP3-associated inflammatory diseases
Tang H, Zou X, Chen P, Wang Y, Gao S, Wang T, Xu Y, Ji S. Broxyquinoline targets NLRP3 to inhibit inflammasome activation and alleviate NLRP3-associated inflammatory diseases. International Immunopharmacology 2025, 156: 114687. PMID: 40253767, DOI: 10.1016/j.intimp.2025.114687.Peer-Reviewed Original ResearchConceptsExperimental autoimmune encephalomyelitisNLR family pyrin domain-containing 3Inflammasome activationInflammatory diseasesASC speck formationInflammasome-associated diseasesNEK7-NLRP3 interactionDamage signalingNF-kB pathwayHost defensePyrin domain-containing 3Speck formationAIM2 inflammasome activationActivation of NLRP3 inflammasomeFamily pyrin domain-containing 3Autoimmune encephalomyelitisMurine modelInterleukin-1bIL-1BInhibiting inflammasome activationNLRP3 inflammasome inhibitorAntimicrobial drugsNF-kBProteinTherapeutic agents
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply